Biomarkers for Optimization and Personalization of Anti-TNFs in Pediatric Inflammatory Bowel Disease

The use of biological drugs has improved outcomes in pediatric inflammatory bowel disease (IBD). Prediction of the response to biological drugs would be extremely useful in IBD, and even more so in children, who are still growing physically and psychologically. Specific clinical, biochemical, and ge...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sara Salvador-Martín, Alejandra Melgarejo-Ortuño, Luis A. López-Fernández
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	biomarkers pharmacogenomics personalized medicine inflammatory bowel disease infliximab adalimumab Pharmacy and materia medica RS1-441
Acceso en línea:	https://doaj.org/article/b275a7c3d7d14dff9e7bd172375fb3fe
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b275a7c3d7d14dff9e7bd172375fb3fe
record_format	dspace
spelling	oai:doaj.org-article:b275a7c3d7d14dff9e7bd172375fb3fe2021-11-25T18:40:41ZBiomarkers for Optimization and Personalization of Anti-TNFs in Pediatric Inflammatory Bowel Disease10.3390/pharmaceutics131117861999-4923https://doaj.org/article/b275a7c3d7d14dff9e7bd172375fb3fe2021-10-01T00:00:00Zhttps://www.mdpi.com/1999-4923/13/11/1786https://doaj.org/toc/1999-4923The use of biological drugs has improved outcomes in pediatric inflammatory bowel disease (IBD). Prediction of the response to biological drugs would be extremely useful in IBD, and even more so in children, who are still growing physically and psychologically. Specific clinical, biochemical, and genetic parameters are considered predictive of response to biological drugs, although few studies have been carried out in children with IBD. In this review, we present current evidence on biological treatments used in pediatric IBD and the available biomarkers of response. We examine demographics, clinical characteristics, biomarkers (genetic, genomic, and cellular), and microbiota.Sara Salvador-MartínAlejandra Melgarejo-OrtuñoLuis A. López-FernándezMDPI AGarticlebiomarkerspharmacogenomicspersonalized medicineinflammatory bowel diseaseinfliximabadalimumabPharmacy and materia medicaRS1-441ENPharmaceutics, Vol 13, Iss 1786, p 1786 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	biomarkers pharmacogenomics personalized medicine inflammatory bowel disease infliximab adalimumab Pharmacy and materia medica RS1-441
spellingShingle	biomarkers pharmacogenomics personalized medicine inflammatory bowel disease infliximab adalimumab Pharmacy and materia medica RS1-441 Sara Salvador-Martín Alejandra Melgarejo-Ortuño Luis A. López-Fernández Biomarkers for Optimization and Personalization of Anti-TNFs in Pediatric Inflammatory Bowel Disease
description	The use of biological drugs has improved outcomes in pediatric inflammatory bowel disease (IBD). Prediction of the response to biological drugs would be extremely useful in IBD, and even more so in children, who are still growing physically and psychologically. Specific clinical, biochemical, and genetic parameters are considered predictive of response to biological drugs, although few studies have been carried out in children with IBD. In this review, we present current evidence on biological treatments used in pediatric IBD and the available biomarkers of response. We examine demographics, clinical characteristics, biomarkers (genetic, genomic, and cellular), and microbiota.
format	article
author	Sara Salvador-Martín Alejandra Melgarejo-Ortuño Luis A. López-Fernández
author_facet	Sara Salvador-Martín Alejandra Melgarejo-Ortuño Luis A. López-Fernández
author_sort	Sara Salvador-Martín
title	Biomarkers for Optimization and Personalization of Anti-TNFs in Pediatric Inflammatory Bowel Disease
title_short	Biomarkers for Optimization and Personalization of Anti-TNFs in Pediatric Inflammatory Bowel Disease
title_full	Biomarkers for Optimization and Personalization of Anti-TNFs in Pediatric Inflammatory Bowel Disease
title_fullStr	Biomarkers for Optimization and Personalization of Anti-TNFs in Pediatric Inflammatory Bowel Disease
title_full_unstemmed	Biomarkers for Optimization and Personalization of Anti-TNFs in Pediatric Inflammatory Bowel Disease
title_sort	biomarkers for optimization and personalization of anti-tnfs in pediatric inflammatory bowel disease
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/b275a7c3d7d14dff9e7bd172375fb3fe
work_keys_str_mv	AT sarasalvadormartin biomarkersforoptimizationandpersonalizationofantitnfsinpediatricinflammatoryboweldisease AT alejandramelgarejoortuno biomarkersforoptimizationandpersonalizationofantitnfsinpediatricinflammatoryboweldisease AT luisalopezfernandez biomarkersforoptimizationandpersonalizationofantitnfsinpediatricinflammatoryboweldisease
_version_	1718410858507272192

Biomarkers for Optimization and Personalization of Anti-TNFs in Pediatric Inflammatory Bowel Disease

Ejemplares similares